Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Operating Expenses (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Operating Expenses for 8 consecutive years, with -$102.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Expenses fell 547.95% year-over-year to -$102.9 million, compared with a TTM value of $43.5 million through Sep 2025, down 68.49%, and an annual FY2024 reading of $39.0 million, down 63.77% over the prior year.
  • Operating Expenses was -$102.9 million for Q3 2025 at X4 Pharmaceuticals, down from $81.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $91.5 million in Q2 2024 and bottomed at -$102.9 million in Q3 2025.
  • Average Operating Expenses over 5 years is $23.0 million, with a median of $25.2 million recorded in 2023.
  • The sharpest move saw Operating Expenses surged 254.4% in 2024, then plummeted 547.95% in 2025.
  • Year by year, Operating Expenses stood at $29.1 million in 2021, then fell by 11.97% to $25.6 million in 2022, then fell by 1.48% to $25.2 million in 2023, then surged by 237.43% to $85.0 million in 2024, then crashed by 221.06% to -$102.9 million in 2025.
  • Business Quant data shows Operating Expenses for XFOR at -$102.9 million in Q3 2025, $81.1 million in Q2 2025, and -$19.7 million in Q1 2025.